The DOI matches its Crossref record.
Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA
Open accessAbstract
The thrombin receptor [protease-activated receptor-1 (PAR-1)] is overexpressed in highly metastatic melanoma cell lines and in patients with metastatic lesions. Activation of PAR-1 leads to cell signaling and up-regulation of genes involved in adhesion, invasion, and angiogenesis. Herein, we stably silence PAR-1 through the use of lentiviral short hairpin RNA and found significant decreases in both tumor growth (P < 0.01) and metastasis (P < 0.001) of highly metastatic melanoma cell lines in vivo. The use of viruses for therapy is not ideal as it can induce toxic immune responses and possible gene alterations following viral integration. Therefore, we also used systemic delivery of PAR-1 small interfering RNA (siRNA) incorporated into neutral liposomes [1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)] to decrease melanoma growth and metastasis in vivo. Significant decreases in tumor growth, weight, and metastatic lung colonies (P < 0.001 for all) were found in mice treated with PAR-1 siRNA-DOPC. The in vivo effects of PAR-1 on invasion and angiogenesis were analyzed via immunohistochemistry. Concomitant decreases in vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-2 expression levels, as well as decreased blood vessel density (CD31), were found in tumor samples from PAR-1 siRNA-treated mice, suggesting that PAR-1 is a regulator of melanoma cell growth and metastasis by affecting angiogenic and invasive factors. We propose that siRNA incorporated into DOPC nanoparticles could be delivered systemically and used as a new modality for melanoma treatment. [Cancer Res 2008;68(21):9078–86]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yao, J., Yang, M., & Duan, Y. (2014) · Chemical Reviews · doi:10.1021/cr200359p · Cited by 944
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Self-citationLiposomal siRNA nanocarriers for cancer therapy
Ozpolat, B., Sood, A. K., & Lopez-Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 442
Self-citationTargeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Landen, C. N., Goodman, B., Katre, A. A., Steg, A. D., Nick, A. M., Stone, R. L., Miller, L. D., Mejia, P. V., Jennings, N. B., Gershenson, D. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0563 · Cited by 382
Self-citation
Metadata
- Authors
- Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., Leslie, M. C., Vivas-Mejia, P. E., Lopez-Berestein, G., Sood, A. K., & Bar-Eli, M.
- Venue
- Cancer Research
- Published
- 2008-10-30
- Volume
- 68
- Issue
- 21
- Pages
- 9078-9086
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2100808905
- Cited by
- 163
- References
- 0
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2397
- The paper
- Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., Leslie, M. C., Vivas-Mejia, P. E., Lopez-Berestein, G., Sood, A. K., & Bar-Eli, M. (2008). Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.